Logo for Ventyx Biosciences Inc

Ventyx Biosciences Investor Relations Material

Latest events

Logo for Ventyx Biosciences Inc

Q1 2024

Ventyx Biosciences
Logo for Ventyx Biosciences

Q1 2024

9 May, 2024
Logo for Ventyx Biosciences

Investor Update

11 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Ventyx Biosciences Inc

Access all reports
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel oral therapies designed to treat patients with autoimmune and inflammatory disorders. The company's approach involves selectively modulating key immune targets to create differentiated medicines. Ventyx Biosciences is working on several promising drug candidates, including a selective allosteric tyrosine kinase type 2 inhibitor and a sphingosine 1 phosphate receptor modulator, which are in various stages of clinical trials targeting conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Additionally, they are developing inhibitors targeting the NLRP3 inflammasome. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.